CommentUrgent need for pragmatic trial platforms in severe asthma
References (11)
- et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)
Respir Med
(2014) - et al.
Integrating real-life studies in the global therapeutic research framework
Lancet Respir Med
(2013) Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
Lancet Respir Med
(2017)- et al.
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J
(2014)
There are more references available in the full text version of this article.
Cited by (17)
Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
2024, Otolaryngologic Clinics of North AmericaThe emergence of new biologics for severe asthma
2019, Current Opinion in PharmacologyCitation Excerpt :These clinical characteristics are now considered typical of the severe eosinophilic asthma phenotype [39]. Currently, there are no head-to-head studies comparing the efficacy of the 3 anti-IL-5 biologics yet, but one trial comparing omalizumab with mepolizumab in severe combined allergic and eosinophilic asthma is underway (PREDICTUMAB) [40]. Nonetheless, there are some differences between these biologics which may be relevant to clinicians.
Biologics for paediatric severe asthma: trick or TREAT?
2019, The Lancet Respiratory MedicineIs Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?
2023, American Journal of Respiratory and Critical Care MedicineAsthma and Tobacco Smoking
2022, Journal of Personalized Medicine
© 2018 Elsevier Ltd. All rights reserved.